ライフサイエンスコーパス: skin reaction

1 o bind HLA-DR did not elicit an inflammatory skin reaction.

2 covered by EORTC systems including radiation skin reaction.

3 3 toxicities were hypertension and hand-foot-skin reaction.

4 stant to IgE-mediated cutaneous inflammatory skin reaction.

5 ant role in Fc(gamma)R-mediated inflammatory skin reaction.

6 ulatory properties predicted for SAg-induced skin reactions.

7 n of drug and radiation did not modify acute skin reactions.

8 ediate (IH) or delayed (DH) hypersensitivity skin reactions.

9 history of athlete's foot but also caused IH skin reactions.

10 ; adverse effects were occasional mild local skin reactions.

11 ective, yet with limitations owing to strong skin reactions.

12 in treatment were prospectively examined for skin reactions.

13 c anaphylaxis and to participate in allergic skin reactions.

14 cities were restricted to grade 1 to 2 local skin reactions.

15 patients (95.2%) experienced transient local skin reactions: 1 (4.8%) herpes zoster, 3 (14.3%) transa

16 atment-related toxicities included hand-foot skin reaction (10%), hypertension (4%), fatigue (2%), an

17 grades) consisted of local DC injection site skin reactions (100%), transient post-DC infusion chills

18 sorders (18 [11%] vs 12 [8%]), and hand-foot skin reaction (12 [8%] and none).

19 n grade 3 or 4 adverse events were hand-foot skin reaction (154 [28%] of 559 patients in the sorafeni

20 s were common, most frequently hand and foot skin reaction (16 patients, 33%), diarrhoea (five patien

21 Adverse events included hand-foot skin reaction (22 [54%]), generalized pigment dilution a

22 ere hypertension (31 of 132, 23%), hand-foot skin reaction (26 of 132, 20%), and diarrhoea (seven of

23 tients [5%] in the placebo group), hand-foot skin reaction (47 patients [13%] vs one [1%]), fatigue (

24 tigue (9.5%), diarrhea (8.0%), and hand-foot skin reaction (5.1%).

25 sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).

26 events in the sorafenib group were hand-foot skin reaction (76.3%), diarrhoea (68.6%), alopecia (67.1

27 er in the sorafenib group included hand-foot skin reaction (8.6% v 0.3%), fatigue (7.3% v 3.6%), rash

28 higher related to regorafenib were hand-foot skin reaction (83 patients, 17%), fatigue (48, 10%), dia

29 ant patients, 22 (19.8%) had heparin-induced skin reactions (95% CI, 13% to 29%).

30 ipsilateral forearm resulting in a positive skin reaction, a clear increase in IFN-gamma ELISPOT cou

31 lorectal cancer who had developed no or mild skin reactions after 21 days of treatment at the standar

32 mediated allergic diseases with little local skin reaction and a minimal risk of anaphylaxis.

33 b and correlated with reduced acute allergic skin reaction and mast cell degranulation.

34 atients in stratum two had grade 3 hand-foot skin reaction and/or rash as dose-limiting toxicities (D

35 mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.

36 risk for unusually intense radiation-induced skin reactions and late tissue damage from high-dose int

37 th more patients developing chills and local skin reactions and more patients stopping PIXY321 due to

38 owever, p38alpha inhibitors produced adverse skin reactions and other toxic effects that often outwei

39 vents were skin rash/desquamation, hand-foot skin reaction, and fatigue; 9% of patients discontinued

40 f actinic keratoses (primary outcome), local skin reactions, and immune activation parameters were as

41 ccus vaccines, delayed-type hypersensitivity skin reactions, and mucosal defense (secretory immunoglo

42 ecially nonhematologic AEs such as diarrhea, skin reactions, and neuropathy.

43 Chemotherapy skin reactions are more likely toxic than allergic react

44 Urticarial skin reactions are one of the most frequent problems see

45 recommended in adults with only generalized skin reactions as it results in significant improvements

46 The typical skin reaction associated with MEK inhibitors is a papulo

47 ntinib were evaluated for the development of skin reactions at each treatment visit from October 2012

48 emas, as well as from localized inflammatory skin reactions at pegylated IFN-alpha injection sites, w

49 s that appeared to be treatment-related were skin reactions at the injection site.

50 Chemokine profiles of inflammatory skin reactions at the injection sites reflected an IFN-a

51 tamine-induced sensations, dysesthesias, and skin reactions but not the sensations and dysesthesias e

52 existing liver disease or concomitant severe skin reactions compared with patients without.

53 ater incidence of nausea, sleep disturbance, skin reactions, constipation, and depression, with only

54 Patients with >/= grade 2 skin reactions continued on standard-dose cetuximab plus

55 mmon adverse effects, most notably hand-foot skin reaction, diarrhea, and hypertension, compared with

56 the incidence and causes of heparin-induced skin reactions during pregnancy in a prospective cohort

57 Expected skin reactions for an average patient are presented in t

58 (n = 44) was associated with an increase in skin reactions >/= grade 2 compared with standard (n = 4

59 city, hyperkeratotic folliculitis, hand-foot skin reaction, hair changes, verrucous papillomas, kerat

60 4%), hypertension (18% v 12%), and hand-foot skin reaction/hand- foot syndrome (HFSR/HFS; 90% v 66%);

61 h a cutaneous adverse event called hand-foot skin reaction (HFSR), in which sites of pressure or fric

62 Nine patients (1%) had concomitant severe skin reactions; implicated agents were lamotrigine, azit

63 to 4 mucositis in 98%, dysphagia in 88%, and skin reaction in 85%.

64 orded one serious adverse event, which was a skin reaction in a child allocated to placebo.

65 irizine) on type I hypersensitivity itch and skin reaction in AD using a patient and examiner-blinded

66 ity, human basophil activation, and positive skin reaction in sensitized patients.

67 nces of stomatitis/pharyngitis and hand-foot skin reaction in the continuous arm.

68 high-dose group; only one (an acute allergic skin reaction in the low-dose group) was assessed to be

69 uded esophagitis in six patients and grade 3 skin reaction in three patients.

70 red in 1.98% (95% CI, 1.50%-2.57%), allergic skin reactions in 1.80% (95% CI, 1.34%-2.37%), heparin-i

71 Protein IV elicited DH skin reactions in subjects with a history of athlete's f

72 re associated with a reduction in late-phase skin reactions induced by whole allergens and bronchial

73 rently available with regard to fluoroscopic skin reactions is based on a table published in 1994.

74 luded diarrhea, nausea, vomiting, mucositis, skin reactions, liver test abnormalities, and infusion-r

75 r clinical phenotypes of NSAID-induced acute skin reactions manifesting with angioedema, urticaria, o

76 nificantly higher maximum physician-assessed skin reaction (moist desquamation, 28.5% vs 6.6%, P < .0

77 on grade 3 adverse events included hand-foot skin reaction, musculoskeletal pain, and fatigue.

78 atment-related adverse events were hand-foot skin reaction (n = 10); neutropenia (n = 7); fatigue (n

79 The most common adverse events were skin reactions occurring in 49 (48%) of 103 CGM particip

80 Local skin reactions peaked between days 3 and 8 and declined

81 among arms were found in incidence of acute skin reaction, pneumonitis, dyspnea, cough, dysphagia, o

82 r (VEGF) are features of late-phase allergic skin reactions, previously proposed as a model of CSU.

83 se events (AEs) included diarrhea, hand-foot-skin reaction, rash, and hypertension.

84 ons, constipation, and depression, with only skin reactions reaching statistical significance (14.4%

85 e patients developed hematuria and one had a skin reaction resembling grade 3 hand-foot syndrome.

86 ls (RS = 0.53, P = .03) and allergen-induced skin reactions (RS = 0.63, P = .008).

87 were PPIX photobleaching and clinical local skin reactions, supported by noninvasive reflectance mea

88 ed serious adverse events included hand-foot skin reaction (ten [2%]), abnormal hepatic function (fou

89 fined protein associated with both DH and IH skin reactions; these reactions are characterized by dis

90 e reaction was headache; aseptic meningitis, skin reactions, thromboembolic events, and renal tubular

91 trongly associated with early-onset BCC were skin reaction to first summer sun for 1 hour (severe sun

92 MC1R, number of moles, skin reaction to first summer sun for 1 hour, and hair a

93 25 pulmonary TB patients who had a positive skin reaction to mumps and/or candida antigens showed pe

94 ble-adjusted RR = 0.98, 95% CI: 0.92, 1.05), skin reaction to prolonged sun exposure (for painful bur

95 using hair color, skin tanning ability, and skin reaction to prolonged sun exposure as surrogate mea

96 e ambient UVR, latitude, daily rainfall, and skin reaction to prolonged sunlight (R(2) = 0.30).

97 on the magnitude of the early and late phase skin reactions to intact allergens.

98 viduals that can range in severity from mild skin reactions to severe and life-threatening anaphylaxi

99 a significantly higher rate of grade 2 to 3 skin reactions under cetuximab treatment.

100 ecorded, and the incidence of CHG-associated skin reactions was 1.2 per 1000 days (95% CI 0.60-2.02).

101 The frequency of adverse skin reactions was similar in the two groups.

102 patients with 1 or more TEAEs (largely local skin reactions) was similar across all groups in year 1:

103 IH skin reactions were associated with a positive RAST (14/

104 The positive skin reactions were found mostly for grass pollen (n = 1

105 Local skin reactions were most intensified in AFXL-pretreated

106 No serious skin reactions were noted during either study period.

107 ) plus irinotecan, patients with </= grade 1 skin reactions were randomly assigned to standard-dose (

108 Catheter-colonization, CR-BSIs, and skin reactions were secondary endpoints.

109 xicities including mucositis, dysphagia, and skin reactions were severe but tolerable.

110 Skin reactions, when present, are well tolerated and onl

111 l wheal formation and complete resolution of skin reactions within 7days, and generated no systemic a